Bioactive scaffold regenerates arteries from within

EU-funded biotechnology researchers have developed a novel treatment for atherosclerosis, the narrowing and hardening of arteries that is the leading underlying cause of death and disability in Europe.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Bosnia and Herzegovina
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Bosnia and Herzegovina
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


 

Published: 22 May 2019  
Related theme(s) and subtheme(s)
Health & life sciencesBiotechnology  |  Major diseases  |  Public health
Research policySeventh Framework Programme
SMEs
Countries involved in the project described in the article
Italy  |  Netherlands  |  Spain  |  Switzerland  |  United Kingdom
Add to PDF "basket"

Bioactive scaffold regenerates arteries from within

image

© freshidea #184516362, 2019 source: stock.adobe.com

Atherosclerosis is a common, potentially serious condition caused by a build-up of fatty material in the lining of the artery walls. It can lead to coronary artery disease, stroke or kidney problems, and existing treatments tend to be only short-term fixes.

In response to this public health challenge, EU-funded project THE GRAIL developed a new therapeutic strategy using a soft, compliant and intelligent ‘scaffold’ made of bioactive material to trigger the regeneration of diseased areas of blood vessels. This novel medical device could soon undergo the first clinical trials in humans.

The scaffold is made of biomimetic protein – which mimics existing proteins in the body – and is known as a synthesised intimal layer. The material is bio-resorbable, meaning it dissolves into the body once healthy arterial tissue has been restored. It should provide a more effective and longer-lasting solution than the therapeutic options currently available to atherosclerosis patients.

‘As the primary cause of cardiovascular disease, atherosclerosis has been the focus of considerable research leading to rather effective treatments. But these treatments have a major shortcoming: they are mostly short-term solutions, failing to restore vessel integrity in the long term,’ says project coordinator Davide De Lucrezia of Explora Biotech in Italy.

Effective, long-term treatment

Currently, patients diagnosed with atherosclerosis are typically treated with one of two methods: bypass surgery, in which blood flow is redirected to divert it around the diseased artery; or angioplasty, in which a balloon catheter is inserted and inflated to enlarge the artery walls.

However, many patients have to return to hospital within a few years as scarring from the surgery, recurring plaque build-up and other complications cause the treated blood vessels to start narrowing again.

The treatment developed by THE GRAIL researchers overcomes these issues. Instead of bypassing or artificially inflating diseased arteries, the team’s solution involved using the thin tube of a catheter, a minimally invasive technique, to insert the synthesised intimal layer into the diseased blood vessel.

Made of biopolymers based on elastine-like proteins, the soft scaffold includes bioactive molecules that are capable of recruiting the patient’s own endothelial cells. These cells, which line the interior surface of blood vessels, support regeneration from within the diseased and stiffened area of the artery.

A dedicated spin-off

‘We demonstrated the scaffold’s full biocompatibility in vitro and safety in vivo, and preliminary results on efficacy are extremely encouraging,’ De Lucrezia says. ‘Thanks to five years of EU support, we were able to progress THE GRAIL project from a simple sketch on a paper to a working prototype, paving the way for the commercial exploitation of the results.’

Three SME partners in THE GRAIL have set up a dedicated spin-off company that owns the intellectual property generated in the project and will engage with larger companies capable of supporting sales. The consortium has also sought to exploit by-products of the research, for instance, testing a new technique for peripheral vascular bypass surgery.

Meanwhile, expertise gained in the project has allowed Explora to offer advanced in-vivo models for safety and efficacy testing of advanced medical devices, making the company one of the leading SMEs in Europe in the field of advanced therapy medicinal product testing.

The project partners are negotiating investment from venture capital firms to develop the technology, potentially leading to the first clinical trials in human patients. If successful, THE GRAIL’s synthesised intimal layer could be used in surgery within a few years, addressing a critical need for effective, long-term treatment for atherosclerosis patients.

Project details

  • Project acronym: THE GRAIL
  • Participants: Italy (Coordinator), Spain, Switzerland, United Kingdom, the Netherlands
  • Project N°: 278557
  • Total costs: € 7 804 024
  • EU contribution: € 5 998 438
  • Duration: January 2012 to December 2016

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project details